SOURCE: ViroCyt, Inc.

ViroCyt, Inc.

July 15, 2016 08:30 ET

ViroCyt® Acquired by Sartorius

BROOMFIELD, CO--(Marketwired - July 15, 2016) - ViroCyt®, a leader in rapid virus quantification, announced today that it has been acquired by Sartorius, a leading international pharmaceutical and laboratory tools provider. The approximate valuation of the transaction is $16M.

The importance of viruses as both a health threat and as a tool for addressing a growing list of diseases continues to increase at a significant pace. Examples include new viral vaccines, protein therapeutics produced from viruses and the use of viruses as gene delivery vectors. A major roadblock in the development of products created either directly from viruses or indirectly using virus-based systems, has been the lack of real time virus quantification methods. In response to this unmet need, ViroCyt has developed and commercialized a suite of products that enable direct, biologically-specific quantification of viruses in minutes, rather than the days or weeks required by more traditional approaches.

"We are adding a very innovative bioanalytical tool to our Lab Products & Services portfolio that will enable our customers to obtain lab results much faster and reduce the time to clinic for virus-based pharmaceuticals," said Michael Melingo, member of the Sartorius Group Executive Committee. Added Robert Kline, ViroCyt President and CEO, "The worldwide reach and outstanding reputation of Sartorius will accelerate the adoption of the Virus Counter technology. ViroCyt is proud to join the Sartorius family and the partnership is a positive development for our customers, employees and shareholders."

About ViroCyt

ViroCyt, Inc. was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at

About Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than EUR1.1B in 2015. More than 6,200 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe. To learn more, visit

Contact Information

  • Contact Information

    Dr. Michael Artinger
    Vice President, Marketing & Strategic Partnering

    ViroCyt, Incorporated